Relationship of Lp-PLA2 levels in maternal serum and placenta with hypertensive disorders of pregnancy
WANG Jing1, DONG Xing2, ZHANG Xuejun1, SHANG Lixin1
1. Department of Gynecology and Obstetrics,2. Department of General Surgery, the Seventh Medical Center of Chinese PLA General Hospital, Beijing 100700,China
Abstract：Objective To investigate the relationship between Lp-PLA2 levels in maternal serum and placenta and hypertensive disorders of pregnancy. Methods The levels of Lp-PLA2 in serum and placenta of 60 patients with hypertensive disorders of pregnancy (19 cases of gestational hypertension, 25 cases of mild preeclampsia, and 16 cases of severe preeclampsia) and 20 normal pregnant women (control group) were measured by enzyme-linked immunosorbent assay and immunohistochemistry. The relationship between levels of Lp-PLA2 and hypertensive disorders of pregnancy was analyzed. Results 1) The expression level of Lp-PLA2 in placenta of patients with hypertensive disorders of pregnancy was significantly higher than that of the control group (P<0.05), so was the expression level of Lp-PLA2 in the mild preeclampsia group (P<0.05). The level in the severe preeclampsia group was significantly higher than that of the mild preeclampsia group (P<0.05). 2) The level of maternal serum Lp-PLA2 was significantly higher than that of the control group(P<0.05). With the aggravation of the disease, the level of Lp-PLA2 increased gradually. There was significant difference between the two groups (all P<0.05). 3) There was a positive correlation between the levels of Lp-PLA2 in serum and in placenta of patients with hypertensive disorders of pregnancy (r=0.435, P< 0.05). Conclusions The increase of Lp-PLA2 levels may be related to the occurrence of hypertensive disorders of pregnancy. The change of Lp-PLA2 levels in maternal serum may be used as a monitoring indicator of the disease.
Tarca A L, Romero R, Benshalom T N, et al. The prediction of early preeclampsia: results from a longitudinal proteomics study [J]. PLoS One, 2019, 14(6): e0217273.
[2]
Jia K, Ma L J, Wu S Y, et al. Serum levels of complement factors C1q, Bb, and H in normal pregnancy and severe Pre-Eclampsia [J]. Med Sci Monit, 2019, 25(9): 7087-7093.
[3]
Tomimatsu T, Mimura K, Matsuzaki S, et al. Preeclampsia: maternal systemic vascular disorder caused by generalized endothelial dysfunction due to placental antiangiogenic factors [J]. Int J Mol Sci, 2019, 20(17): 4246-4264.
[4]
Olaoye T, Oyerinde O O, Elebuji O J, et al. Knowledge, perception and management of pre-eclampsia among health care providers in a maternity hospital [J]. Int J MCH AIDS, 2019, 8(2): 80-88.
[5]
Alahakoon T I, Medbury H J, Williams H, et al. Lipid profiling in maternal and fetal circulations in preeclampsia and fetal growth restriction-a prospective case control observational study [J]. BMC Pregnancy Childbirth, 2020, 20(1): 61-71.
[6]
Tenório M B, Ferreira R C, Moura F A, et al. Cross-Talk between oxidative stress and inflammation in preeclampsia[J].Oxid Med Cell Longev, 2019, 2019(11): 8238727-8238753.
[7]
Huang F B, Wang K, Shen J H. Lipoprotein-associated phospholipase A2: The story continues [J]. Med Res Rev, 2020, 40(1): 79-134.
[8]
Jackisch L, Kumsaiyai W, Moore J D, et al. Differential expression of Lp-PLA2 in obesity and type 2 diabetes and the influence of lipids [J]. Diabetologia, 2018 ,61(5): 1155-1166.
[9]
谢 幸. 妇产科学[M]. 9版. 北京:人民卫生出版社. 2018:83-91.
[10]
Siddiqui M K, Kennedy G, Carr F, et al. Lp-PLA2 activity is associated with increased risk of diabetic retinopathy: a longitudinal disease progression study [J]. Diabetologia, 2018, 61(6): 1344-1353.
[11]
Li J W, Wang H, Tian J, et al. Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome [J]. Medicine (Baltimore), 2018, 97(28): e11517.
[12]
Chen B F, Deng Y, Xu X, et al. Effect of selective thrombus aspiration on serum lipoprotein-associated phospholipase A2 in Patients with ST-Elevation myocardial infarction undergoing primary percutaneous coronary intervention with high thrombus burden [J]. Acta Cardiol Sin, 2018, 34(3): 233-241.
[13]
Tian Y, Jia H, Li S, et al. The associations of stroke, transient ischemic attack, and/or stroke-related recurrent vascular events with Lipoprotein-associated phospholipase A2: a systematic review and meta-analysis [J]. Medicine (Baltimore), 2017, 96(51): e9413.
[14]
Cao J, Hsu Y H, Li S, et al. Structural basis of specific interactions of Lp-PLA2 with HDL revealed by hydrogen deuterium exchange mass spectrometry [J]. J Lipid Res, 2013, 54(1): 127-133.
[15]
Paik J K, Kim M, Kim M, et al. Circulating Lp-PLA2 activity correlates with oxidative stress and cytokines in overweight/obese postmenopausal women not using hormone replacement therapy [J]. Age (Dordr) , 2015, 37(2): 32-42.
[16]
He S, Chousterman B G, Fenn A, et al. Lp-PLA2 antagonizes left ventricular healing after myocardial infarction by impairing the appearance of reparative macrophages [J]. Circ Heart Fail, 2015, 8(5): 980-987.
[17]
Balc E Ö, Ekmekçi H, Güngör Z, et al. Evaluation of Lp-PLA2 mass, vitronectin and PAI-1 activity levels in patients with preeclampsia [J]. Arch Gynecol Obstet, 2015, 292(1):53-58.
Dhamoon M S, Cheung Y K, Moon Y P, et al. Interleukin-6 and lipoprotein-associated phospholipase A2 are associated with functional trajectories [J]. PLoS One, 2019,14(4):e0214784.
[20]
Güngör Z B, Tüten A, Ekmekçi H, et al. Possible effects of lipoprotein-associated phospholipase A2 single-nucleotide polymorphisms on cardiovascular risk in patients with preeclampsia [J]. J Matern Fetal Neonatal Med, 2018, 31(23):3119-3127.
2020, Vol. 31 
